[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Genital Warts (GWs)- Epidemiology Forecast to 2030

May 2020 | 102 pages | ID: GB2D8A41BE25EN
DelveInsight

US$ 2,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Genital Warts (GWs)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Genital Warts in the United States.

Geography Covered
  • The United States
Study Period: 2017–2030

Genital Warts Disease Understanding

Genital warts (GWs) are transmitted by having sexual contact with someone who already has them, and may be found on the outside of genitals. Some types, which cause cancer, result in the growth of lesions on a woman's cervix. It is possible to get genital warts, HPV infection, even if they are not visible. They look like flesh-colored bumps that have a cauliflower-like appearance, and are usually flat, papular, or pedunculated growths on the genital mucosa, occurring in clusters. They can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual contact with an infected person. Potentially cancer-causing HPV strains are spread by sexual intercourse, anal sex, and oral sex. Moreover, genital Warts is also known as anogenital warts (AGWs) or condylomata acuminata.

Genital Warts Epidemiology

The Genital Warts (GWs) epidemiology division provides the insights about historical and current patient pool and forecasted trend the United States. The epidemiology data for Genital Warts are studied through all possible division to give a better understanding about the Disease scenario in the United States. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Genital Warts Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Incidence of GWs, Gender-specific Cases, Age-specific Cases of Genital Warts, HPV type associated with GWs and Anatomical Location of Warts) in the United States from 2017–2030.

The DelveInsight report also provides the epidemiology trends observed in the US during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of diagnosed incident cases of Genital Warts (GWs) in the US was found to be 4,65,000, in the year 2017.

Report Scope
  • The report covers detailed overview of Genital Warts explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Genital Warts in the United States
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the United States with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Total Diagnosed Incidence of GWs, Gender-specific Cases, Age-specific Cases of Genital Warts, HPV type associated with GWs and Anatomical Location of Warts in the US
Key strengths
  • 11 Year Forecast of Genital Warts epidemiology
  • The US Coverage
  • Total incident cases of GWs
  • Incident Cases according to segmentation: Total Diagnosed Incidence of GWs, Gender-specific Cases, Age-specific Cases of Genital Warts, HPV type associated with GWs and Anatomical Location of Warts
Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
1 KEY INSIGHTS

2 EXECUTIVE SUMMARY OF GWS

3 SWOT ANALYSIS FOR GWS

4 DISEASE BACKGROUND AND OVERVIEW

4.1. Introduction
4.2. Natural History
4.3. Causes and Risks
4.4. Symptoms
4.5. Pathophysiology
4.6. Clinical Presentation
4.7. Complications of Untreated HVP Infection
4.8. Diagnosis

5 TREATMENT AND MANAGEMENT

6 VACCINES

6.1. Gardasil: Merck
6.2. Cervarix: GlaxoSmithKline
6.3. Comparison
6.4. Differences

7 EPIDEMIOLOGY AND PATIENT POPULATION

7.1. Key Findings
7.2. Country Wise-Epidemiology
7.3. United States
  7.3.1. Assumptions and Rationale
  7.3.2. Diagnosed incidence of GWs in the United States
  7.3.3. Gender Specific Diagnosed Cases of GWs in the United States
  7.3.4. Age Specific Diagnosed Cases of GWs in the United States
  7.3.5. Anatomical Location of Genital Warts in the United States

8 UNMET NEEDS

9 ORGANIZATIONS RELATED TO GWS

10 CASE STUDIES

10.1. A Case Report of Genital Warts
10.2. A Case Report of Condyloma Acuminata

11 APPENDIX

11.1. References
11.2. Report Methodology

12 DELVEINSIGHT CAPABILITIES

13 DISCLAIMER

14 ABOUT DELVEINSIGHT

LIST OF TABLES

Table 1: Summary of Genital Warts (GWs) Market, Epidemiology, and Key Events (2017–2030)
Table 2: Low-risk HPV versus High-risk HPV
Table 3: Treatment Modalities
Table 4: Treatments and their Advantages
Table 5: Enhancing the efficacy of imiquimod
Table 6: Gardasil versus Cervarix
Table 7: Diagnosed Incident Population of GWs in the United States (2017–2030)
Table 8: Gender Specific Diagnosed Cases of GWs in the United States (2017–2030)
Table 9: Age Specific Diagnosed Cases of GWs in the United States (2017–2030)
Table 10: Anatomical Location of GWs in the United States (2017–2030)
Table 11: Organizations contributing toward Genital Warts


LIST OF FIGURES

Figure 1: SWOT Analysis
Figure 2: Different Types of Warts
Figure 3: HPV Structure and Function
Figure 4: HPV Structure and Function
Figure 5: Infection by HPV
Figure 6: Checklist for Initial Consultation
Figure 7: Checklist for providing Treatment
Figure 8: Treatment Algorithm
Figure 9: Newer Simplified Treatment Algorithm
Figure 10: Algorithm for Treatment Selection
Figure 11: Algorithm for Treatment Selection in Pregnant Patients
Figure 12: Diagnosed Incidence of GWs in the United States (2017–2030)
Figure 13: Gender Specific Diagnosed Cases of GWs in the United States (2017–2030)
Figure 14: Age Specific Diagnosed Cases of GWs in the United States (2017–2030)
Figure 15: Anatomical Location of GWs in the United States (2017–2030)
Figure 16: Unmet needs for GWs


More Publications